search

Active clinical trials for "Macular Degeneration"

Results 21-30 of 1337

VOY-101 in Advanced Non-Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

The Phase 1 safety study of VOY-101 comprises a two dose Cohort escalation, followed by a Phase 2a.

Recruiting10 enrollment criteria

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular...

Neovascular Age-related Macular Degeneration

Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.

Recruiting16 enrollment criteria

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen...

Geographic Atrophy

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.

Recruiting14 enrollment criteria

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection...

Wet Age-related Macular Degeneration

The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.

Recruiting24 enrollment criteria

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases...

Eye DiseasesRetinitis Pigmentosa5 more

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Eye diseases

Recruiting12 enrollment criteria

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration...

Age-Related Macular Degeneration

KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.

Recruiting2 enrollment criteria

QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration

Intermediate Age-Related Macular Degeneration

This is a phase 2, randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Recruiting23 enrollment criteria

Atrophic Age-related Macular Degeneration (AMD) Treated With Intravitreal Injections of Umbilical...

Dry Age-related Macular Degeneration

The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular Degeneration (AMD)

Recruiting11 enrollment criteria

Efficacy and Safety of RC28-E Versus Aflibercept

Wet Age-related Macular Degeneration

This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.

Recruiting50 enrollment criteria

Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease

Stargardt Disease

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease. This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.

Recruiting20 enrollment criteria
1234...134

Need Help? Contact our team!


We'll reach out to this number within 24 hrs